Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Research & Development (2022 - 2025)

Praxis Precision Medicines has reported Research & Development over the past 4 years, most recently at $77.5 million for Q4 2025.

  • Quarterly results put Research & Development at $77.5 million for Q4 2025, up 37.7% from a year ago — trailing twelve months through Dec 2025 was $267.1 million (up 75.26% YoY), and the annual figure for FY2025 was $267.1 million, up 75.26%.
  • Research & Development for Q4 2025 was $77.5 million at Praxis Precision Medicines, up from $65.8 million in the prior quarter.
  • Over the last five years, Research & Development for PRAX hit a ceiling of $77.5 million in Q4 2025 and a floor of $17.3 million in Q3 2023.
  • Median Research & Development over the past 4 years was $36.2 million (2022), compared with a mean of $41.3 million.
  • Biggest five-year swings in Research & Development: tumbled 51.56% in 2023 and later soared 206.11% in 2024.
  • Praxis Precision Medicines' Research & Development stood at $28.3 million in 2022, then crashed by 35.09% to $18.4 million in 2023, then soared by 206.11% to $56.3 million in 2024, then soared by 37.7% to $77.5 million in 2025.
  • The last three reported values for Research & Development were $77.5 million (Q4 2025), $65.8 million (Q3 2025), and $63.0 million (Q2 2025) per Business Quant data.